Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cigna Corp (CI) vs TG Therapeutics Inc (TGTX) Price & Performance

Cigna CorpTrade
TG Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

Cigna Corp vs TG Therapeutics Inc — how do they compare? Cigna Corp trades at $274.34 (market cap $73.56B), while TG Therapeutics Inc trades at $50.11 (market cap $7.64B). The key difference: Cigna Corp is far larger — about 9.6× TG Therapeutics Inc's market cap, and Cigna Corp pays a 2.24% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.

CITGTX
Market Cap
$73.56B$7.64B
Sector
HealthHealth
52-Week High
$311.00$59.06
52-Week Low
$244.41$26.94
Enterprise Value
$98.27B$7.84B
Dividend Yield
2.24%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cigna Corp

Cigna (CI) trades at $278.40, down 1.45% on the day, with a bearish technical signal but strong fundamentals including a P/E of 11.51 and ROE of 15.49%. Recent Q2 2026 earnings beat expectations at $7.78 per share, and the company raised its full-year EPS guidance. The stock is supported by consistent dividend payments and robust cash flow from operations of $9.60 billion in 2025.

The outlook is positive with a consensus price target of $338.90, implying 22% upside. Key opportunities include steady earnings growth and capital returns, while risks involve healthcare cost pressures and competitive dynamics. Analyst sentiment is strongly bullish with 73.68% buy ratings, though technical indicators suggest near-term caution.

TG Therapeutics Inc

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

About Cigna Corp

Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM services were greatly expanded by its 2018 merger with Express Scripts and are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, but it also operates in government programs, such as Medicare Advantage. The company operates mostly in the U.S. with 15 million medical members covered as of the end of 2020, but its services extend internationally, covering another 2 million people.

Read more on CI

About TG Therapeutics Inc

TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.

Read more on TGTX